Could a migraine drug stop dizziness fast?
NCT ID NCT07435090
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether rimegepant, a drug used for migraines, can quickly reduce dizziness from conditions like vestibular migraine. About 370 adults with moderate to severe dizziness will receive either rimegepant plus betahistine or betahistine alone. The main goal is to see if dizziness drops from moderate/severe to none/mild within one hour.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- rimegepant
- What this could lead to
- If it works, this could provide a new, fast-acting treatment option for acute dizziness attacks.
- What could go wrong
- This is an early-phase trial (Phase 2/3) with a moderate size, so results may not confirm effectiveness or safety for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 370 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age between 18 and 65 years; 2. Spontaneous dizziness without cochlear symptoms, with moderate or severe symptom intensity. The severity of dizziness is assessed based on the Vertigo or Dizziness Visual Analog Scale (VAS) score, and this study included patients with dizziness exceeding 4 points on the VAS score; 3. The patient has experienced at least 3 similar dizziness attacks in the past, with each attack lasting more than 2 hours; 4. The accompanying symptoms or related medical history during the attack period meet any of the following criteria: 1) Migraine-like headache (unilateral, pulsatile, moderate to severe, aggravated by activity; at least 2 items); 2) Photophobia and phonophobia; 3) Nausea or vomiting; 4) Visual aura; 5) Nystagmus; 6) The patient has a personal history of migraine; 7) Severe kinetosis; 8) Family history of migraine; 9) Typical triggering factors for migraine (menstrual period, alcohol consumption, sleep disturbances); 5. The patient has completed emergency laboratory examination and imaging evaluation to preliminarily rule out dizziness attacks caused by other reasons; 6. The patient can sign an informed consent form. Exclusion Criteria: 1. New focal neurological signs; 2. History of previous stroke or transient ischemic attack; 3. ABCD2 score ≥ 4 points; 4. Presence of other vestibular peripheral vertigo disorders, such as benign paroxysmal positional vertigo, Meniere's disease, vestibular neuritis, sudden deafness, etc.; 5. Unexplained hearing abnormalities; 6. History of serious internal medical or mental illnesses, such as coronary heart disease (acute coronary syndrome), severe heart failure (New York Heart Association Functional Classification class II or above), severe arrhythmia (such as severe bradycardia, third-degree atrioventricular block, ventricular tachycardia, etc.), severe liver dysfunction (alanine aminotransferase or aspartate aminotransferase exceeding three times the upper limit of normal), severe renal dysfunction (serum creatinine level exceeding twice the upper limit of normal), uncontrolled severe hypertension (blood pressure above 180/120 mmHg), active malignant tumors, and uncontrolled mental illness; 7. Pregnant or breastfeeding women; 8. Self-administered vestibular inhibitors or CGRP drugs after the dizziness attack; 9. History of intolerance or allergy to rimegepant use; 10. Anticipated inability to comply with research requirements.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Benign recurrent vertigo are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye training may calm Neck-Related dizziness
- Could a symptom registry unmask hidden migraine variants?
- Could a stick of gum soothe a spinning world?
- Can a Dual-Task test predict falls in the elderly?
- Wearable patch aims to catch hidden heart rhythms that holter monitors miss
- New study targets lingering concussion symptoms in teens